spawns Wave Life Sciences ( NASDAQ: WVE ) added ~54% premarket Tuesday after announcing encouraging clinical trial results for WVE-003, an experimental therapy it co-develops with Takeda ( NYSE: TAK ) for a neurological condition called Huntington’s disease (HD). Citing 24-week data from its Phase 1b/2a SELECT-HD trial, the Singapore-based company said WVE-003 led to an average decline of 46% in mutant huntingtin (mHTT) protein, the accumulation of which results in clinical manifestations of the disease. Based on 28 weeks of data, including 12 weeks of follow-up, the company added that the experimental therapy, which belongs to a drug class called antisense oligonucleotide, preserved the wild-type huntingtin (wtHTT) protein, which is crucial for neuronal function.
While clinical effects were statistically significant, in terms of tolerability, WVE-003 was found to be safe and well-tolerated, and the study participants didn’t experience serious adverse events, WVE added. “These results represent a significant achievement for Wave, for the oligonucleotide field, and most importantly, for the HD community,” Wave’s ( WVE ) chief development officer, Anne-Marie Li-Kwai-Cheung, remarked. Given the robustness of the data, the company said it would pursue a potential accelerated approval for the drug during discussions with regulators on its future development.
More on Takeda, Wave Life Sciences, etc. Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit D.
